Clinical trial
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA)…
NCT03810144 · Sequenom, Inc., Industry · Completed
Key facts
| NCT number | NCT03810144 |
|---|---|
| Title | Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test |
| Official title | Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test on Clinical Outcomes and Pharmaceutical Utilization in Patients With Rheumatoid Arthritis: A Prospective, Randomized Study |
| Acronym | CareFirst |
| Lead sponsor | Sequenom, Inc., Industry |
| Collaborators | Laboratory Corporation of America Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Genetic |
| Interventions | Vectra MBDA Test |
| Enrollment | 444 |
| Start date | Oct 22, 2018 |
| Primary completion | Aug 16, 2022 |
| Completion | Oct 16, 2022 |
| First posted | Jan 18, 2019 |
| Last update posted | Aug 9, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: